PMS-METOPROLOL-L TABLET
Land: Kanada
Tungumál: enska
Heimild: Health Canada
Vara einkenni
(SPC)
24-09-2020
Sum skjöl fyrir þessa vöru eru ekki tiltæk eins og er, þú getur sent beiðni til þjónustu við viðskiptavini okkar og við munum láta þig vita um leið og við getum fengið þau.
Senda beiðni.
Senda beiðni.
Virkt innihaldsefni:
METOPROLOL TARTRATE
Fáanlegur frá:
PHARMASCIENCE INC
ATC númer:
C07AB02
INN (Alþjóðlegt nafn):
METOPROLOL
Skammtar:
50MG
Lyfjaform:
TABLET
Samsetning:
METOPROLOL TARTRATE 50MG
Stjórnsýsluleið:
ORAL
Einingar í pakka:
100/500/1000
Gerð lyfseðils:
Prescription
Lækningarsvæði:
BETA-ADRENERGIC BLOCKING AGENTS
Vörulýsing:
Active ingredient group (AIG) number: 0111923002; AHFS:
Leyfisstaða:
APPROVED
Leyfisdagur:
1997-03-10
Vara einkenni
PRODUCT MONOGRAPH
PR
PMS-METOPROLOL-L
Metoprolol Tartrate Tablets, USP
25 mg, 50 mg and 100 mg
Β-ADRENERGIC RECEPTOR BLOCKING AGENT
PHARMASCIENCE INC.
6111 Royalmount Ave., Suite 100
Montréal, Canada
H4P 2T4
DATE OF REVISION:
September 24, 2020
www.pharmascience.com
SUBMISSION CONTROL NO: 240530
_pms-METOPROLOL-L Product Monograph _
_Page 2 of 39_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................4
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
..................................................................................................11
DRUG INTERACTIONS
..................................................................................................13
DOSAGE AND ADMINISTRATION
..............................................................................17
OVERDOSAGE
................................................................................................................20
ACTION AND CLINICAL PHARMACOLOGY
............................................................21
STORAGE AND STABILITY
..........................................................................................24
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................25
PART II: SCIENTIFIC INFORMATION
...............................................................................26
PHARMACEUTICAL INFORMATION
..........................................................................26
DETAILED PHARMACOLOGY
.....................................................................................27
TOXICOLOGY
...............................
Lestu allt skjalið
